pharmaphorum20h
BeiGene abandons TIGIT antibody after lung cancer flop
TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months ...
CURE3d
COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...
CURE3d
First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...
PharmExec4d
Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC
Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...
Targeted Oncology4d
The Targeted Pulse: Explaining Survivorship Care and Other Positive Developments Across Cancers
Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.
J&J unit ordered to pay $1.64B in HIV drug marketing case, Reuters reports
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64B after a jury found it liable in a ...